ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2790

Screening of Patients with Adult-Onset Idiopathic Polyarteritis Nodosa for Deficiency of Adenosine Deaminase 2

Oskar Schnappauf1, Monique Stoffels2, Ivona Aksentijevich2, Daniel L. Kastner2, Peter C. Grayson3, David Cuthbertson4, Simon Carette5, Sharon A. Chung6, Lindsy J. Forbess7, Nader A. Khalidi8, Curry L. Koening9, Carol Langford10, Carol A. McAlear11, Paul A. Monach12, Larry W. Moreland13, Christian Pagnoux14, Philip Seo15, Jason Springer16, Antoine G. Sreih17, Kenneth J. Warrington18, Steven R. Ytterberg18 and Peter A. Merkel19, 1NHGRI, National Institutes of Health, Bethesda, MD, 2Metabolic, Cardiovascular, and Inflammatory Disease Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 3National Institute of Arthritis, Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, MD, 4Biostatistics and Informatics, Department of Pediatrics, Department of Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, 5Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, 6Russell/Engleman Rheumatology Research Center, University of California, San Francisco, San Francisco, CA, 7Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 8Rheumatology, McMaster University, Hamilton, ON, Canada, 9Rheumatology, Division of Rheumatology, University of Utah, Salt Lake City, UT, 10Rheumatic and Immunologic Diseases, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, 11Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 12Section of Rheumatology, Boston University School of Medicine, Boston, MA, 13Division of Rheumatology and Clinical Immunology, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, 14Division of Rheumatology, Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, 15Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, MD, 16Department of Internal Medicine, The University of Kansas Medical Center, Division of Allergy, Clinical Immunology & Rheumatology, Kansas City, KS, 17Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 18Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN, 19Division of Rheumatology and the Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: anti-TNF therapy, Genetic disorders, polyarteritis nodosa and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: 5T046 ACR Abstract: Plenary Session III (2785–2790)

Session Type: ACR Plenary Session

Session Time: 11:00AM-12:30PM

Background/Purpose:

Deficiency of adenosine deaminase 2 (DADA2) is the first described type of monogenic vasculitis. Patients usually present in childhood, but age of onset, disease severity, and organ involvement of DADA2-associated vasculitis is highly variable and clinical features overlap with the typical features of polyarteritis nodosa (PAN). This study aimed to test the prevalence of DADA2 in patients with presumed idiopathic PAN.

Methods:

Patients (n=117) with idiopathic PAN, all of whom tested negative for hepatitis B virus infection, were screened for mutations in ADA2 (formerly known as CECR1). DNA was extracted from whole blood by standard methods. Standard PCR amplification and Sanger sequencing was performed for the 9 coding exons of the ADA2 gene. To further assess the pathogenicity of identified variants on a functional level, ADA2 activity was determined using the adenosine deaminase assay kit from Diazyme.

Results:

Eight of 117 patients (6.8%) were identified as having rare missense variants in ADA2 with a minor allele frequency of < 0.005. Four patients (3.4%) were homozygous or compound heterozygous for variants in ADA2. Of the 7 distinct variants present in these 4 patients, G47A, G47W, R169Q, E328K, F355L, and G383S had previously been reported as causative for DADA2. The remaining variant, P106S, is a rare variant predicted to be damaging to protein function by the PROVEAN algorithm. Four additional patients were carriers for the monoallelic variants R34W, T65M, M309I, and V349I. R34W was reported in DADA2 before, while the 3 remaining variants are of unknown clinical significance.

Serum samples were available on patients with the G383S/G383S and E328K/F355L genotypes and measurements showed markedly reduced ADA2 enzyme activity, comparable to levels seen in patients with DADA2. ADA2 activity in the serum of 2 of the monoallelic carriers was not reduced, confirming the non-pathogenicity of T65M and V349I. The median age at diagnosis for the 4 patients with biallelic ADA2 mutations was considerably younger (median 23.0 years, range 17.4-24.4) than for the 4 patients with heterozygous ADA2 variants (median 42.0 years, range 16.5-59.0) or the other 109 patients in the cohort (median 47.0 years, range 33.3-56.7) (p=0.04). There were no marked differences in the types of clinical manifestations between patients with or without ADA2 mutations, including neurologic disease.

Conclusion:

This is the first study to report biallelic pathogenic variants in ADA2 in patients with adult-onset, HBV-negative PAN, and demonstrates that DADA2 accounts for a subset of patients with idiopathic PAN. Given the potential efficacy of TNF-inhibitors in DADA2, that anti-TNF treatment is not the conventional therapy in PAN, and the consequences for other family members, these findings suggest that ADA2 testing should be considered in patients with HBV-negative idiopathic PAN, especially in patients with an early onset of this potentially life-threatening disease.


Disclosure: O. Schnappauf, None; M. Stoffels, None; I. Aksentijevich, None; D. L. Kastner, None; P. C. Grayson, None; D. Cuthbertson, None; S. Carette, None; S. A. Chung, None; L. J. Forbess, None; N. A. Khalidi, None; C. L. Koening, None; C. Langford, None; C. A. McAlear, None; P. A. Monach, None; L. W. Moreland, None; C. Pagnoux, None; P. Seo, None; J. Springer, None; A. G. Sreih, None; K. J. Warrington, GlaxoSmithKline, 2,Eli Lilly and Co., 2,Sanofi, 5; S. R. Ytterberg, None; P. A. Merkel, None.

To cite this abstract in AMA style:

Schnappauf O, Stoffels M, Aksentijevich I, Kastner DL, Grayson PC, Cuthbertson D, Carette S, Chung SA, Forbess LJ, Khalidi NA, Koening CL, Langford C, McAlear CA, Monach PA, Moreland LW, Pagnoux C, Seo P, Springer J, Sreih AG, Warrington KJ, Ytterberg SR, Merkel PA. Screening of Patients with Adult-Onset Idiopathic Polyarteritis Nodosa for Deficiency of Adenosine Deaminase 2 [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/screening-of-patients-with-adult-onset-idiopathic-polyarteritis-nodosa-for-deficiency-of-adenosine-deaminase-2/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/screening-of-patients-with-adult-onset-idiopathic-polyarteritis-nodosa-for-deficiency-of-adenosine-deaminase-2/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology